US Edition
Increasing Transparency in the Biologic Patent Dance
Summary by The Regulatory Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Increasing Transparency in the Biologic Patent Dance
Biologics—drugs made from organic materials, such as vaccines—are thought to be an important factor driving high drug prices. In the United States, biologics make up over half of prescription medicine spending while accounting for only approximately 3 percent of all prescriptions. In a recent article, Robin Feldman and Gideon Schor of the University of California College of Law, San Francisco argue that increasing biologics competition is import…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
